Iobenguane sulfate I-123

Identification

Name
Iobenguane sulfate I-123
Accession Number
DB09546
Description

Iobenguane sulfate I-123 is a radiopharmaceutical used in gamma-scintigraphy of adrenergically inervated tissues [FDA Label].

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 640.26
Monoisotopic: 639.953520274
Chemical Formula
C16H22I2N6O4S
Synonyms
  • Iobenguane sulfate I 123

Pharmacology

Indication

For use in the diagnostic imaging of adrenergically inervated tissues for the purposes of detecting metastatic pheochromocytoma or neuroblastoma [FDA Label]. Also used to assess the sympathetic inervation of the myocardium via determination of the heart to mediastinum ratio of radioactivity in patients with New York Heart Association class II or III heart failure.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Iobenguane I-123 is taken up by and stored in adrenergic nerve terminals allowing for the radiographic imaging of adrenergically inervated organs and tissues [FDA Label].

Mechanism of action

Iobenguane I-123 is transported into adrenergic nerve terminals via the noradrenaline uptake transporter [FDA Label]. It is rapidly cleared from systemic circulation and collected in adrenergically invervated tissues. This allows for gamma-scintigraphic imaging of these tissues and their associated organs for diagnostic purposes.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Metabolized to m-iodohippuric acid and free radioiodide [FDA Label]. The metabolism of iobenguane I-123 and the enzymes involved has not been well studied.

Hover over products below to view reaction partners

Route of elimination

Primarily eliminated via the urine as the parent compound (70-90%) [FDA Label]. A small amount is eliminated in the urine as m-iodohippuric acid (</10%) and free radioiodide (</6%). Less than 1% is eliminated in the feces. Iobenguane I-123 is initially rapidly cleared from circulation follwed by a slow clearance from other tissues over 4 days. Retention is the longest in highly adrenergically inervated tissues like the adrenal medulla, heart, and salivary glands. Iobenguane I-123 is not cleared by dialysis.

Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

As a radiopharmaceutical, iobenguane I-123 carries the risk of radiation toxicity if administered in innappropriately large doses or in patients with renal insufficency [FDA Label]. Fequent voiding of the bladder is encouraged to minimize the radiation dose to the bladder.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
AcarboseAcarbose may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Iobenguane sulfate I-123 which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
AcrivastineAcrivastine may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
i 123 MIBG meta iodobenzylguanidineInjection, powder, lyophilized, for solution25 mCi/1IntravenousAnazao Health Corporation2012-05-23Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
i 123 MIBG meta iodobenzylguanidineIobenguane sulfate I-123 (25 mCi/1)Injection, powder, lyophilized, for solutionIntravenousAnazao Health Corporation2012-05-23Not applicableUs

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as iodobenzenes. These are aromatic compounds containing one or more iodine atoms attached to a benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Iodobenzenes
Alternative Parents
Organic sulfuric acids / Aryl iodides / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Organopnictogen compounds / Organoiodides / Organic oxides / Hydrocarbon derivatives
Substituents
Aromatic homomonocyclic compound / Aryl halide / Aryl iodide / Carboximidamide / Guanidine / Hydrocarbon derivative / Iodobenzene / Organic 1,3-dipolar compound / Organic nitrogen compound / Organic oxide
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
23X1185WBO
CAS number
80663-95-2
InChI Key
XNACDNPGABUBFR-FKNPGSCZSA-N
InChI
InChI=1S/2C8H10IN3.H2O4S/c2*9-7-3-1-2-6(4-7)5-12-8(10)11;1-5(2,3)4/h2*1-4H,5H2,(H4,10,11,12);(H2,1,2,3,4)/i2*9-4;
IUPAC Name
bis(N-{[3-(¹²³I)iodophenyl]methyl}guanidine); sulfuric acid
SMILES
OS(O)(=O)=O.NC(=N)NCC1=CC([123I])=CC=C1.NC(=N)NCC1=CC([123I])=CC=C1

References

General References
Not Available
PubChem Compound
56840904
PubChem Substance
347827877
ChemSpider
32701571
RxNav
1427223
ChEMBL
CHEMBL3989523
FDA label
Download (302 KB)
MSDS
Download (100 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous25 mCi/1
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
water solubilitySolubleMSDS
Radioactivity (mCi/mL)2MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.1 mg/mLALOGPS
logP1.42ALOGPS
logP1.69ChemAxon
logS-3.4ALOGPS
pKa (Strongest Basic)11.75ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area61.9 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity68.61 m3·mol-1ChemAxon
Polarizability21.91 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da

Drug created on November 30, 2015 12:10 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates